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Abstract: The coagulation and fibrinolytic pathways regulate hemostasis and thrombosis, 
and an imbalance in these pathways may result in pathologic hemophilia or thrombosis. The 
plasminogen system is the primary proteolytic pathway for fibrinolysis, but also has important 
proteolytic functions in cell migration, extracellular matrix degradation, metalloproteinase 
activation, and hormone processing. Several studies have demonstrated plasmin cleavage and 
inactivation of several coagulation factors, suggesting plasmin may be not only be the primary 
fibrinolytic enzyme, but may have anticoagulant properties as well. The objective of this review 
is to examine both in vitro and in vivo evidence for plasmin inactivation of coagulation, and to 
consider whether plasmin may act as a physiological regulator of coagulation. While several studies 
have demonstrated strong evidence for plasmin cleavage and inactivation of coagulation factors 
FV, FVIII, FIX, and FX in vitro, in vivo evidence is lacking for a physiologic role for plasmin 
as an anticoagulant. However, inactivation of coagulation factors by plasmin may be useful as a 
localized anticoagulant therapy or as a combined thrombolytic and anticoagulant therapy.
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Introduction
Thrombosis, either arterial or venous, is a fatal and disabling consequence of cardio-
vascular disease, the leading cause of mortality and morbidity in developed countries.1 
Thrombosis occurs as a consequence of vascular injury, generally occurring at a vulner-
able atherosclerotic plaque or under low-flow conditions, and imbalance between the 
pathways that regulate thrombus formation and/or dissolution.1 The plasminogen (Plg) 
system (Figure 1) is the major proteolytic pathway responsible for dissolution of blood 
clots. Increased clot formation or decreased degradation is the central event in thrombotic 
disease.2,3 Plasmin is a broad-spectrum serine protease, and increasing evidence has 
implicated critical roles for Plg in the cleavage of nonfibrinolytic substrates, including 
extracellular matrix proteins,5,6 metalloproteinases,7,8 growth factors,9,10 hormones,11,12 
and coagulation factors.13–17 Since plasmin inactivates coagulation factors by cleavage, 
in addition to its fibrinolytic function in the proteolytic degradation of fibrin (ogen), 
plasmin may also act as an anticoagulant. The purpose of this review is to examine both 
in vitro and in vivo evidence for plasmin inactivation of coagulation, and to consider 
whether plasmin may act as a physiological regulator of coagulation.
Plasminogen system
The Plg system (Figure 1) is composed of: a zymogen, Plg; the bioactive enzyme, 
plasmin; and the Plg activators, ie, tissue Plg activator (tPA) and urokinase Plg activator Vascular Health and Risk Management 2010:6 200
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(uPA) and its primary receptor (uPAR), Plg activator 
inhibitors, primarily plasminogen activator inhibitor-1 
(PAI-1); and the primary plasmin inhibitor, α2-antiplasmin 
(AP). Plg is a single-chain glycoprotein composed of five 
triple-loop kringle domains, and a serine protease domain.18 
The kringle domains regulate the binding to inhibitors, cells, 
and substrates through their expression of lysine binding 
sites (LBS) which bind to proteins with carboxyl-terminal 
lysines or conformational mimetics of these residues. Plg is 
produced primarily by the liver, circulates in plasma at a high 
concentration (2 µM), and is also found in high concentra-
tions in interstitial fluid. Binding of Plg to cell surfaces and 
extracellular matrix accelerates its activation by Plg activators 
to plasmin. Plasmin is an enzyme with broad specificity,2 
but the Plg activators, uPA and tPA, have much narrower 
specificity and are widely distributed. PAI-1 binds to uPA 
and tPA, blocking their activation of Plg. AP binds initially 
to the LBS of plasmin and then to its catalytic site. Plasmin 
bound to fibrin or cell surfaces is substantially protected from 
AP inactivation because its LBS are occupied.
Coagulation factors
Several studies have documented the cleavage and inactiva-
tion by plasmin of coagulation factors, including Factor (F)V, 
FVIII, FIX, and FX (Figure 2). These coagulation factors 
circulate in the plasma at low concentrations, and FVIII, FIX 
are components of the intrinsic coagulation pathway and FV 
and FX are components of the prothrombinase complex in the 
common coagulation pathway. FV and FVIII, nonenzymatic 
cofactors, are similar in structure and include two A domains 
(copper binding) at the N-terminus followed by a connecting B 
domain and then an A3 domain and C domain at the C-terminal. 
FIX and FX are serine proteases and are similar in structure, 
containing heavy and light chains with a vitamin K-dependent 
domain, two growth factor domains and a catalytic domain.
Factor V
FV is a nonenzymatic cofactor in the prothrombinase complex 
in the common coagulation pathway. Prothrombinase activity 
is required for thrombin formation and is essential for clot 
formation. FV is produced by the liver and megakaryocytes, 
circulates in the plasma, and is present in platelet a-granules.19 
FVa is inactivated by plasmin cleavage in both heavy and light 
chains.13,20 Plasmin cleaves the heavy chain of FV at three 
sites, Lys309, Lys310, and Arg313, releasing the A2 domain 
and causing inactivation of the cofactor.21,22 The plasmin 
cleavages are accelerated in the presence of a membrane 
surface.21 Measuring thrombin formation20,22 or plasma clot-
ting21 determines the functional activity of FV. In humans, 
a deficiency of FV causes excessive bleeding. A common 
genetic mutation in FV, FV Leiden, inhibits protein C, an 
endogenous anticoagulant, and causes persistent thrombosis.23 
In mice, a FV deficiency is embryonically lethal, and FV 
Leiden in mice causes spontaneous thrombosis.24,25
Factor VIII
FVIII is a component of the intrinsic pathway and the 
primary source of circulating FVIII is the liver. FVIII is a 
Figure 1 The plasminogen system.
Notes: Plasminogen activators are tPA and uPA; PAI-1 inhibits tPA and uPA reducing activation of plasminogen to plasmin; α2-antiplasmin inhibits plasmin activity.
Abbreviations: PAI-1, plasminogen activator inhibitor-1; tPA, tissue plasminogen activator; uPA, urokinase plasminogen activator.
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nonenzymatic cofactor, and deficient or defective protein 
causes a bleeding disorder, hemophilia A. FVIII is required 
for the anionic phospholipid surface-dependent conversion 
of FX to FXa by FIXa. Numerous studies have suggested that 
plasmin inactivates FVIII,14,27 and recently Nogami et al28,29 
identified the plasmin cleavage site at Arg336 as responsible 
for FVIII inactivation and a plasmin interactive site in the 
A2 domain. Degradation of FVIII by plasmin results in a 
decrease in clotting activity, and deficient FVIII mice offer 
a model for hemophilia A.30
Factor IX
FIX is a serine protease synthesized in the liver as a single-
chain glycoprotein (57 kD), which circulates in plasma and 
is activated by either FXIa or tissue factor (TF) and FVIIa. 
Plasmin cleaves FIX at Arg145 and Arg180 and at three 
other sites to yield the inactivate form.15 Tissue Plg activator-
catalyzed lysis of fibrin formed in human plasma generated 
fragments of FIX and decreased FIX activity,15 suggesting 
tPA activated Plg was involved in the FIX fragmentation. 
Clotting time is inhibited by plasmin-cleaved FIX and FIXa 
fragments. Deficient mice are a model for hemophilia B and 
exhibit excessive tail bleeding and reduced activated partial 
thromboplastin time.31
Factor X
FX is a serine protease synthesized in the liver and is a 
component of the prothrombinase complex that functions 
to generate thrombin. Plasmin-mediated cleavage of FXa 
exposes a Plg binding site16,32 and inhibits coagulation. In 
the presence of anionic phospholipid, FX and FXa enhance 
Plg activation by tPA33,34 to plasmin. Thus, plasmin cleavage 
of FX not only inhibits coagulation but also enhances 
fibrinolysis. FX deficiency causes partial embryonic lethality 
and fatal neonatal bleeding.35,36
Tissue factor protein inhibitor
In addition to the documented cleavage by plasmin of the four 
coagulation factors, plasmin can inactivate the anticoagulant 
issue factor protein inhibitor (TFPI), a Kunitz-type protease 
inhibitor. TFPI with FXa inhibits the tissue factor-FVIIa 
complex, reducing the initiation of the extrinsic pathway. 
Plasmin cleaves recombinant TFPI (rTFPI) at several sites 
(K86–T87, R107–G108, R199–A200, K249–G250).15 rTFPI, 
added to plasma with uPA, is degraded, and in the presence 
of aprotinin,17 a catalytic inhibitor of plasmin, degradation 
of TFPI is abolished. Plasmin also degrades constitutive and 
heparin-releasable TFPI (with tPA and Plg) from human 
umbilical vein endothelial cells.37 Whether inactivation of 
TFPI would counteract the anticoagulant activity of plasmin 
cleavage of other factors (FV, FVIII, FIX, FX) is unclear. 
TFPI deficiency produces intrauterine lethality.38
In vivo evidence
Mouse models of thrombosis  
formation and lysis
While the plasmin-cleaved coagulation factors have reduced 
formation of thrombin, there is little in vivo evidence for a 
role of plasmin inactivation of coagulation factors and TFPI. 
However, several studies have alluded to this possibility. 
Matsuno et al39 found that Plg-deficient mice had shorter 
arterial occlusion times after photochemical carotid injury 
Figure 2 Plasmin substrates in the coagulation pathways.
Notes: Shaded boxes are plasmin substrates. Cleavage by plasmin inactivates the substrates. Extrinsic, intrinsic, and common pathways are indicated.
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(Table 1) whereas a deficiency of α2-AP, PAI-1, or vitronectin 
deficiency resulted in delayed occlusion times.39–42 Patency 
of the injured carotids was more rapid in the PAI-1 and AP-
deficient mice than wild-type (WT) mice (Table 1). Occlu-
sion time of the carotid after photochemical injury was not 
different in mice deficient in Plg activators, uPA, or tPA, but 
patency was delayed in the tPA-deficient mice.42 The delay 
of occlusion time by plasmin/Plg inhibitors suggests a pos-
sible anticoagulant effect for plasmin. The marked delay of 
clot lysis time (patency) in the Plg and tPA-deficient mice 
and increased lysis in PAI-1 and AP is consistent with the 
role of plasmin in fibrinolysis. Another widely used model of 
thrombosis in mice is the FeCl3 injury model. In a prelimi-
nary study43 we found there was no difference between the 
WT (17 ± 2 sec, n = 6) and Plg-/- mice (18 ± 4 sec, n = 6) in 
occlusion time after carotid FeCl3 injury (Table 1) in contrast 
with the decrease found in the photochemical model. The 
response to FeCl3 carotid injury was similar in the PAI-1 defi-
cient mice.44,45 With vitronectin-/- mice, one report with FeCl3 
injury had increased occlusion time as with photochemical 
injury, but one study reported a decrease.46 Clot lysis (% 
carotid open after four hours) was markedly delayed in Plg-
deficient mice (17%, 1/7) compared with WT mice (66%, 
2/3).43 The injury to the carotid by FeCl3 is more severe and 
occlusion times are faster, which may account for the lack of 
difference in occlusion time between WT and Plg-/- mice in 
this model. Wang et al47 found that if a lower dose of FeCl3 
was used, a delay in occlusion was detected and a difference 
in mice deficient in coagulation factors were detected at the 
lower dose, but not at the higher dose.
In a tail bleeding/rebleeding assay,48 Plg-/- mice had 
increased bleeding times, but had no difference in rebleed-
ing times (Table 2). In contrast, in PAI-1-deficient mice 
bleeding time was not different to that in the control strain 
(B6), but clot stability time was reduced, consistent with a 
fibrinolytic role of plasmin. The increase in bleeding time in 
Plg-deficient mice may be a reflection of the tissue site51 and 
which coagulation pathway is involved. Mackman49 found 
that mice with low TF and low FVII, both part of the extrinsic 
coagulation pathway, had normal tail bleeding, but in FVIII- 
or FIX-deficient mice bleeding times were increased. These 
results suggest that a role of plasmin as an anticoagulant may 
be pathway- or tissue-dependent.
Regulation of TFPI
An in vivo role for Plg in the regulation of TFPI is not clear. 
Stalboerger et al50 reported that TFPI is released in human 
artery sections by plasmin treatment, suggesting a possible 
increase in the anticoagulant TFPI. However, it was also sug-
gested that plasmin may deplete TFPI in the vascular wall 
and contribute to rethrombosis in atherosclerotic plaque. In 
a sepsis-induced model in baboons,51 immunosuppression of 
TFPI and inhibition of PAI-l led to a decrease in TFPI and 
fibrin accumulation in the lung, suggesting plasmin may play a 
role in proteolysis of TFPI and sepsis-induced coagulation.
In vivo testing for plasmin 
anticoagulant activity
Deficient mice offer potential options for testing the 
anticoagulant activity of plasmin in vivo. There are several 
Table 1 Thrombosis formation and lysis after carotid injury
Mouse genotype Model Time to occlusion Patency Reference
Plg-/-
AP-/-
Photochemical Decreased
Increased
Decreased
Increased
39
PAI-1-/-
AP-/-
Photochemical Increased
Increased
Increased
Increased
39,40
PAI-1-/-
VN-/-
Photochemical Increased
Increased
41
PAI-1-/-
tPA-/-
uPA-/-
Photochemical Increased
NC
NC
Increased
Decreased
NC
42
Plg-/- FeCl3 NC Decreased 43
PAI-1-/- FeCl3 ND Increased 44
PAI-1-/-
VN-1-/-
FeCl3
FeCl3
Increased
Increased
Increased
Increased
45
VN-1-/- FeCl3 Decreased ND 46
Abbreviations: AP, α2-antiplasmin; NC, no change; ND, not determined; PAI-1, plasminogen activator inhibitor-1; Plg, plasminogen; tPA, tissue plasminogen activator; uPA, 
urokinase plasminogen activator; VN, vitronectin.Vascular Health and Risk Management 2010:6 203
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approaches that could be utilized to elucidate the role of 
plasmin in coagulation: 1) Testing the local modulation of 
plasmin in thrombus formation in the photochemical and 
FeCl3 injury models by using Plg-deficient mice and adding 
either microplasmin or plasmin-neutralizing antibodies or 
inhibitors directly to the injured carotid; 2) testing small 
peptides that would inhibit the plasmin cleavage-specific 
coagulation factors; and 3) generating genetically mutated 
coagulation proteins in factor-deficient mice by knocking-in 
the mutated gene. An example would be increasing plasmin in 
FV Leiden mice which are prone to developing spontaneous 
thrombosis, to determine if thrombus formation was reduced. 
Thrombus formation and thrombolysis could be distinguished 
by following the generation of fibrin degradation products. 
Cheng et al52 crossed Plg-deficient and FIX mice and found 
reduced wasting in the double-deficient mice compared with 
the Plg-deficient mice; bleeding and thrombosis were not 
determined. Utilization of genetically altered mice offers 
approaches to test and define the potential of the anticoagu-
lant activity of plasmin in vivo.
Anticoagulant and thrombolytic 
therapy
The two major issues to consider in the treatment of throm-
botic disease are reducing thrombus formation and lysis of 
an existing clot. Often both factors must be treated in the 
same pathological situation. There are several new oral 
anticoagulants that are currently in clinical trials being 
investigated for long-term oral use.53,54 Unlike warfarin, the 
most widely used anticoagulant, these new anticoagulants 
target single proteins in the coagulation pathway and include 
FXa, FIX, FVII/TF, Va/VIIIa, and thrombin inhibitors. These 
are the same coagulation proteins that plasmin inactivates, 
suggesting the possibility that plasmin inactivation may be a 
viable anticoagulant with the added benefit of fibrinolysis.
Thrombolytic agents, primarily Plg activators or their 
derivates, have been developed to promote thrombolysis, but 
the risk of bleeding (reviewed by Ellis and Brener53 and Bottiger 
et al)54 has been a major problem. Numerous clinical53,54 and 
animal55–57 studies have documented the potential for bleed-
ing when tPA, the Plg activator, is administered. Bottiger 
et al54 reported that use of a third-generation Plg activator, 
tenecteplase, a tPA derivative, did not improve the outcome 
when used alone. Recently, strategies other than plasmin acti-
vators have been investigated, such as inhibition of the plasmin 
inhibitors, AP58 and PAI-1.59,60 Plasmin61 and microplasmin, 
a derivative of plasmin, have also been considered for 
use as intravenous thrombolytics.62,63 Plasmin has several 
advantages as a thrombolytic drug,61 including: elimination 
of the need for Plg and its activation; a significant margin of 
safety against bleeding even with high doses; a dose-response 
to plasma fibrinogen; and inhibition of systemic excess by 
AP. Prevention of thrombotic occlusion without excessive 
bleeding is critical in patients with myocardial infarction, 
ischemic stroke, abdominal aortic aneurysm, and peripheral 
artery disease. Topical application of plasmin is used in 
the treatment of macular degeneration,54 vitrectomy,65 and 
ligneous conjunctivitis.66 Comerato67 reports the effective-
ness of catheter-directed intrathrombus thrombolysis with 
plasmin for the treatment of acute lower extremity arterial 
occlusion. Given the advantages of intravenous plasmin, a 
mild anticoagulant and a fibrinolytic, plasmin may be an 
alternative to anticoagulants and thrombolytics that have the 
potential to cause bleeding.
Conclusions
Plasmin cleaves and deactivates FV, FVIII, FIX, and FX 
in vitro and suggests another potential therapeutic strategy 
to regulate thrombotic occlusion. Since plasmin is one of 
several broad-spectrum serine proteases, cleavage by plasmin 
in vitro may not necessarily imply Plg plays this role in vivo. 
In addition, in vivo detection of an anticoagulation role of 
plasmin may be difficult because of its rapid thrombolytic 
activity. Studies in animals are suggestive of an anticoagulant 
effect of plasmin, but there is insufficient evidence to sup-
port a definitive role of plasmin as an anticoagulant in vivo. 
Mice with deficiencies in clotting factors and Plg-pathway 
components are suitable models for defining the in vivo role 
of plasmin in anticoagulation. Plasmin has recently been 
suggested as an ideal thrombolytic therapeutic drug, but may 
also confer mild anticoagulation that would be important 
Table 2 Plg-/- mice have increased bleeding time and PAI-1-/- mice 
have reduced clot stability time in the tail bleeding/rebleeding 
assay
Tail bleeding/rebleeding assay
Bleeding time (sec) Rebleeding time (sec)
WT 79 ± 5 (28)♦ 207 ± 38 (28)
Plg-/- 130 ± 15 (9)♦ 188 ± 86 (9)
B6 99 ± 17 (34) 189 ± 25 (34)*
PAI-1-/- 123 ± 26 (21) 108 ± 30 (21)*
Notes: The mouse tail is warmed in saline, clipped and remains in the saline during 
the time measurements. Bleeding time is the time between the start of bleeding (after 
tail clip) and rebleeding time is the time between the cessation of the bleeding and the 
start of the second bleeding. Statistical difference ♦P  0.05 between WT/Plg+/+ mice 
and Plg-/- mice, and *P  0.0001 for B6 mice compared to PAI-1-/- mice. (Hoover-Plow 
et al. modified from Figure 1, Ref. 48).Vascular Health and Risk Management 2010:6 204
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when both thrombolysis and anticoagulation without excess 
bleeding are required. Further evidence is needed to deter-
mine whether plasmin could be used as a therapeutic agent 
to prevent thrombus formation.
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